Original language | English (US) |
---|---|
Pages (from-to) | 3-22 |
Number of pages | 20 |
Journal | Molecular Psychiatry |
Volume | 26 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2021 |
ASJC Scopus subject areas
- Molecular Biology
- Cellular and Molecular Neuroscience
- Psychiatry and Mental health
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Molecular Psychiatry, Vol. 26, No. 1, 01.2021, p. 3-22.
Research output: Contribution to journal › Editorial › peer-review
}
TY - JOUR
T1 - A Brain Capital Grand Strategy
T2 - toward economic reimagination
AU - Smith, Erin
AU - Ali, Diab
AU - Wilkerson, Bill
AU - Dawson, Walter D.
AU - Sobowale, Kunmi
AU - Reynolds, Charles
AU - Berk, Michael
AU - Lavretsky, Helen
AU - Jeste, Dilip
AU - Ng, Chee H.
AU - Soares, Jair C.
AU - Aragam, Gowri
AU - Wainer, Zoe
AU - Manji, Husseini K.
AU - Licinio, Julio
AU - Lo, Andrew W.
AU - Storch, Eric
AU - Fu, Ernestine
AU - Leboyer, Marion
AU - Tarnanas, Ioannis
AU - Ibanez, Agustin
AU - Manes, Facundo
AU - Caddick, Sarah
AU - Fillit, Howard
AU - Abbott, Ryan
AU - Robertson, Ian H.
AU - Chapman, Sandra B.
AU - Au, Rhoda
AU - Altimus, Cara M.
AU - Hynes, William
AU - Brannelly, Patrick
AU - Cummings, Jeffrey
AU - Eyre, Harris A.
N1 - Funding Information: Conflict of interest JC has provided consultation to Acadia, Actino-gen, Alkahest, Alzheon, AnnovisBio, Avanir, Axsome, BiOasis, Biogen, Cassava, Cerecin, Cortexyme, Cytox, Diadem, EIP Pharma, Eisai, Foresight, GemVax, Genentech, Green Valley, Grifols, Map-light, Merck, Otsuka, Resverlogix, Roche, Samumed, Samus, Signant, Third Rock, and United Neuroscience pharmaceutical and assessment companies. JC has stock options in ADAMAS, MedAvante, QR pharma/AnnovisBio, BiOasis. Ryan Abbott works as an attorney and consult to a variety of commercial enterprises in the life science and information technology fields. AWL reports personal investments in public and private biotech companies, biotech venture capital funds, and biotech mutual funds. He is a director of BridgeBio Pharma and Roivant Sciences, and a member of the Board of Overseers at Beth Israel Deaconess Medical Center and the NIH’s National Center for Advancing Translational Sciences Advisory Council and Cures Acceleration Network Review Board. He is a co-founder and partner of QLS Advisors, a health care analytics company; an advisor to BrightEdge Ventures, the impact fund of the American Cancer Society; and chairman emeritus and senior advisor to AlphaSimplex Group, an asset management company he founded in 1999. CR receives a stipend from the American Association for Geriatric Psychiatry for editing the American Journal of Geriatric Psychiatry; royalty income from the University of Pittsburgh as co-inventor of the Pittsburgh Sleep Quality Inventory. IT reports income and stock in ALTOIDA LLC and has a patent “Apparatus, method and program for determining a cognitive state of a user of a mobile device” pending. HAE receives fees from PRODEO LLC, PreActive Technologies INC and ALTOIDA LLC. CHN had served as a consultant for Lundbeck, Grunbiotics, Servier, Janssen-Cilag, and Eli Lilly, received research grant support from Lundbeck, and speaker honoraria from Servier, Lundbeck, Bristol-Myers Squibb, Organon, Eli Lilly, GlaxoSmithK-line, Janssen-Cilag, Astra-Zenaca, Wyeth, and Pfizer. WDD reports personal fees from Commonwealth Fund, personal fees from AARP, personal fees from Insights to Illuminate, LLC, personal fees from Cognitive Solutions, LLC, personal fees from Oregon Health Care Association, personal fees from Mather LifeWays, personal fees from Splaine Consulting, outside the submitted work. E. Storch reports consulting fees from Levo Therapeutics; Honoraria from International OCD Foundation; and book royalties from Wiley, Elsevier, Springer, American Psychological Association, Oxford, Jessica Kingsley, Funding Information: Funding KS is supported by NIMH, Training the Science of Child Mental Health Treatment, 5T32MH073517-14. MB is supported by a NHMRC Senior Principal Research Fellowship (1059660 and 1156072). JC is supported by KMA; NIGMS grant P20GM109025; NINDS grant U01NS093334; and NIA grant R01AG053798. No other co-authors have funding support to note. AWL gratefully acknowledges funding support from Jean-Jacques DeGroof and other sponsors of the MIT Laboratory for Financial Engineering (https://lfe. mit.edu/about/sponsors/). No funding bodies of AWL had any role in study design, data collection and analysis, decision to publish, or preparation of this paper. No direct funding was received for this study by AWL, who was personally salaried by his institution during the period of writing (though no specific salary was set aside for or given to AWL for the writing of this paper). DJ’s work was supported, in part, by the National Institute of Mental Health R01 grant (R01MH094151-01 to DJ [PI]), and the Sam and Rose Stein Institute for Research on Aging at the University of California San Diego. WDD reports funding from GBHI ALZ UK-20-640170 and from Oregon Health Authority. HL receives grant funding from NIMH, NIA, NCCIH, NIAMS, PCORI, Alzheimer’s Research and Prevention Foundation. E. Storch reports research support from NIH, Texas Higher Education Coordinating Board, Red Cross, Greater Houston Community Foundation, ReBuild Texas. AI is partially supported by grants from CONICET, ANID/FONDAP/15150012, the Interamerican Development Bank (IDB), GBHI ALZ UK-20-639295, and the Multi-partner Consortium to Expand Dementia Research in Latin America (ReDLat; NIH NIA R01 AG057234, Alzheimer’s Association SG-20-725707, Tau Consortium, and Global Brain Health Institute).
PY - 2021/1
Y1 - 2021/1
UR - http://www.scopus.com/inward/record.url?scp=85093931550&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85093931550&partnerID=8YFLogxK
U2 - 10.1038/s41380-020-00918-w
DO - 10.1038/s41380-020-00918-w
M3 - Editorial
C2 - 33100330
AN - SCOPUS:85093931550
SN - 1359-4184
VL - 26
SP - 3
EP - 22
JO - Molecular Psychiatry
JF - Molecular Psychiatry
IS - 1
ER -